Closing the Global Health Innovation Gap: A Role for the Biotechnology Industry in DrugDiscovery for Neglected DiseasesCopyright© 2007 BIO Ventures for Global Health. All rights reserved.This report was written by Joanna E. Lowell with contributions fromChristopher D. Earl, Michael C. Venuti, Wendy Taylor, and Julie S. Klim.
BVGH wishes to thank L.E.K. Consulting for its role in the research underlying this report;the individuals who reviewed this document—Maria Freire, Carl Nathan, Tito Serafini, NatalieBarndt, and the BVGH Board of Directors; Anastasia Semienko, who assisted in the final pushto complete the project; and the many individuals from the global health community andbiopharmaceutical industry who participated in our interviews and shared their enthusiasmand ideas. Special thanks to Dr. Corey Goodman for the initial inspiration for this project.To request additional print copies of this report or other information from BVGH, pleasecontact:BIO Ventures for Global Health1225 Eye Street, NW, Suite 1010 Washington, DC 20005Tel: +1 202.312.9260Fa: +1 443.320.4430E-mail: email@example.com Web: www.bvgh.orgThe full tet of this report is also available online at the BVGH website:http://www.bvgh.org/documents/InnovationMap.pdf Cover Image by J. Mainquist, courtesy of NIH’s National Human Genome Research Institute.The Kalypsys suite of ultra-high throughput robotic technologies can screen the biologicalactivity of more than one million chemical compounds per day.Design and layout by Bussolati Associates.Illustrations for Figures 3.4 and 3.6 by Jennifer Fairman.